Skip to main content

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Publication ,  Journal Article
Sun, C; Dobi, A; Mohamed, A; Li, H; Thangapazham, RL; Furusato, B; Shaheduzzaman, S; Tan, S-H; Vaidyanathan, G; Whitman, E; Hawksworth, DJ ...
Published in: Oncogene
September 11, 2008

The high prevalence of TMPRSS2-ERG rearrangements ( approximately 60%) in prostate cancer (CaP) leads to androgenic induction of the ETS-related gene (ERG) expression. However, the biological functions of ERG overexpression in CaP remain to be understood. ERG knockdown in TMPRSS2-ERG expressing CaP cells induced striking morphological changes and inhibited cell growth both in cell culture and SCID mice. Evaluation of the transcriptome and specific gene promoters in ERG siRNA-treated cells and investigation of gene expression signatures of human prostate tumors revealed ERG-mediated activation of C-MYC oncogene and the repression of prostate epithelial differentiation genes (PSA and SLC45A3/Prostein). Taken together, these data combining cell culture and animal models and human prostate tumors reveal that ERG overexpression in prostate tumor cells may contribute to the neoplastic process by activating C-MYC and by abrogating prostate epithelial differentiation as indicated by prostate epithelial specific markers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncogene

DOI

EISSN

1476-5594

Publication Date

September 11, 2008

Volume

27

Issue

40

Start / End Page

5348 / 5353

Location

England

Related Subject Headings

  • Tumor Cells, Cultured
  • Reverse Transcriptase Polymerase Chain Reaction
  • RNA, Messenger
  • Proto-Oncogene Proteins c-myc
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Promoter Regions, Genetic
  • Oncology & Carcinogenesis
  • Oncogene Proteins, Fusion
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sun, C., Dobi, A., Mohamed, A., Li, H., Thangapazham, R. L., Furusato, B., … Srivastava, S. (2008). TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene, 27(40), 5348–5353. https://doi.org/10.1038/onc.2008.183
Sun, C., A. Dobi, A. Mohamed, H. Li, R. L. Thangapazham, B. Furusato, S. Shaheduzzaman, et al. “TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.Oncogene 27, no. 40 (September 11, 2008): 5348–53. https://doi.org/10.1038/onc.2008.183.
Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008 Sep 11;27(40):5348–53.
Sun, C., et al. “TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.Oncogene, vol. 27, no. 40, Sept. 2008, pp. 5348–53. Pubmed, doi:10.1038/onc.2008.183.
Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan S-H, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008 Sep 11;27(40):5348–5353.

Published In

Oncogene

DOI

EISSN

1476-5594

Publication Date

September 11, 2008

Volume

27

Issue

40

Start / End Page

5348 / 5353

Location

England

Related Subject Headings

  • Tumor Cells, Cultured
  • Reverse Transcriptase Polymerase Chain Reaction
  • RNA, Messenger
  • Proto-Oncogene Proteins c-myc
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Promoter Regions, Genetic
  • Oncology & Carcinogenesis
  • Oncogene Proteins, Fusion